Featured Publications
Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Yap D, Leone A, Wong N, Zhao J, Tey J, Sundar R, Pietrantonio F. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma. JAMA Oncology 2023, 9: 215-224. PMID: 36480211, PMCID: PMC9857522, DOI: 10.1001/jamaoncol.2022.5816.Peer-Reviewed Original ResearchConceptsAdvanced esophageal squamous cell carcinomaImmune checkpoint inhibitorsEsophageal squamous cell carcinomaSquamous cell carcinomaPD-L1 expressionKaplan-Meier curvesLow PD-L1 expressionFirst-line trialsProgression-free survivalDuration of responsePD-L1Overall survivalCell carcinomaRandomized clinical trialsPooled analysisClinical trialsCheckpoint inhibitorsTumor proportionEffect of immune checkpoint inhibitorsLow programmed death ligand 1Benefit of immune checkpoint inhibitorsHazard ratioSurvival dataFirst-line settingICI-based regimens
2024
EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol
Petrillo A, Oudijk L, Sundar R, Daumer C, Casas J, D’Haese D, Mauer M, van Grieken N, Smyth E, Moehler M. EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol. ESMO Gastrointestinal Oncology 2024, 5: 100071. DOI: 10.1016/j.esmogo.2024.100071.Peer-Reviewed Original Research
2023
1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis
Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Barr N, Sundar R. 1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis. Annals Of Oncology 2023, 34: s873. DOI: 10.1016/j.annonc.2023.09.1471.Peer-Reviewed Original ResearchPD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy.
Wong Zhun Hong N, Zhao J, Zhu K, Yap D, Kumarakulasinghe N, Huang Y, Sundar R. PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy. Journal Of Clinical Oncology 2023, 41: e21140-e21140. DOI: 10.1200/jco.2023.41.16_suppl.e21140.Peer-Reviewed Original ResearchNon-small cell lung cancerPD-L1 expressionFirst-line chemotherapyNon-squamous non-small cell lung cancerSquamous non-small cell lung cancerTreated with first-line chemotherapyPhase III randomized trialNegative predictive biomarkerNon-squamous histologyPD-L1 subgroupsPD-L1Tumor progressionSquamous histologyPredictive biomarkersKaplan-MeierAdvanced squamous non-small cell lung cancerAdvanced non-small cell lung cancerPatients treated with first-line chemotherapyRandomized trialsInvestigated PD-L1 expressionRisk of tumor progressionHigh PD-L1Kaplan-Meier (KM) curvesPositive predictive biomarkerImmune checkpoint inhibition
2019
Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer.
Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer. Journal Of Clinical Oncology 2019, 37: e15509-e15509. DOI: 10.1200/jco.2019.37.15_suppl.e15509.Peer-Reviewed Original ResearchPD-L1 expressionPD-L1Gastric cancerEBV-negativeAnti-PD-1 immune checkpoint inhibitorsEBV-encoded RNA in situ hybridizationImmune-evasionProtein expression of PD-L1PD-L1 transcript expressionExpression of PD-L1Resistance to immune checkpoint inhibitionEpstein-Barr virus-positive gastric cancerEpstein-Barr virus-associated gastric cancerImmune checkpoint inhibitionImmune checkpoint inhibitorsPD-L1 immunohistochemistryPrimary tumor resectionPositive gastric cancerGastric cancer patientsEBV-negative samplesSamsung Medical CentreRNA in situ hybridizationCheckpoint inhibitorsCheckpoint inhibitionEBV status
2018
Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes
Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer 2018, 21: 1064-1070. PMID: 29915957, DOI: 10.1007/s10120-018-0851-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedB7-H1 AntigenBiomarkers, TumorCD8 AntigensCohort StudiesDisease-Free SurvivalEpstein-Barr Virus InfectionsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHerpesvirus 4, HumanHumansImmunohistochemistryLymphocytes, Tumor-InfiltratingMaleMiddle AgedPerforinProgrammed Cell Death 1 ReceptorStomach NeoplasmsConceptsPD-L1PD-L1highPD-L1lowEBVaGC samplesImmune-related genesAssociated with worse disease-free survivalGastric cancerPD-L1 immunohistochemistry expressionPD-L1 transcript expressionExpression of PD-L1Levels of PD-L1Epstein-Barr virus-associated gastric cancerTumour-infiltrating lymphocyte patternPD-L1 expressionPD-L1 immunohistochemistryPrimary tumor resectionDisease-free survivalAssociated with higher expressionCases of EBVaGCGastric cancer patientsEBV-negative samplesSamsung Medical CentreAsian Cancer Research GroupImmune genesCancer Research Group
2016
Emerging biomarkers for PD-1 pathway cancer therapy
Lim J, Sundar R, Chnard-Poirier M, Lopez J, Yap T. Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers In Medicine 2016, 11: 53-67. PMID: 27936870, DOI: 10.2217/bmm-2016-0228.Peer-Reviewed Educational MaterialsConceptsPD-L1Predictive biomarkers of responseImmune checkpoint inhibitorsImmune-related toxicitiesPD-L1 expressionPD-L1 inhibitorsBiomarkers of responseTreatment response biomarkersMultiple tumor typesIntermediate end pointsCheckpoint inhibitorsPD-1Predictive biomarkersImmuno-oncologyResponse assessmentTumor typesResponse biomarkersCancer therapyEnd pointsTherapy designBiomarkersFDA registrationTreatmentInhibitorsDifferential responding